Navigation Links
DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
Date:5/5/2011

ent of BESST and receipt of top-line data for POSIDUR, possible licensing transactions relating to TRANSDUR-Sufentanil, future development activities regarding ELADUR, anticipated commencement of a new Phase I trial for ORADUR-ADHD and our other drug candidates and the potential benefits and uses of our drug candidates are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including product non-approval, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, the potential failure of our clinical trials to meet their intended endpoints, our potential failure to maintain our collaborative agreements with third parties or consummate new collaborations and DURECT's (and that of its third party collaborators where applicable) difficulty or failure to obtain approvals from regulatory agencies with respect to its development activities and products, or ability to design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the referenced product candidates, manufacture and commercialize the referenced product candidates, obtain marketplace acceptance of the referenced product candidates, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund its growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-K on March 3, 2011 under the heading "Risk Factors."DURECT CORPORATIONBALANCE SHEET DATA(in thousands)As ofAs ofMarch 31, 2011December 31, 2010 (1)(unaudited)ASSETSCurrent assets:Cash and cash equivalents$
4,830$
,437Short-term investments33,54
'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
2. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
3. DURECT Corporation Announces Third Quarter 2008 Financial Results
4. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
5. Techne Corporation Declares Dividend
6. Techne Corporation Announces Acquisition
7. SynapDx Corporation Licenses Autism Diagnostic Discoveries From Childrens Hospital Boston
8. Vestaron Corporation Announces New Leadership
9. Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia
10. Every Day is Earth Day for Yulex Corporation
11. Veteran Wall Street Securities Analyst Reports on Health Discovery Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... R-Biopharm is proud to announce the RIDASCREEN® Gliadin Competitive ... been accepted by AOAC International as Official First Action method. The AOAC Official ... R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially celiac toxic ...
(Date:7/30/2015)... ... 30, 2015 , ... The 2015 Market Research Report on the Global ... the global Propanol market with a focus on the Chinese situation. Major companies included ... Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... Bedford, NH (PRWEB) , ... July 30, 2015 ... ... efficiency homogenizer for advanced fluid applications and designed for continuous operation up to ... clean-in-place and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... "personal genomics," featuring five of the most outstanding scientists, physicians and ... Bio-IT World Conference & Expo being held April 27-29 at the ... ... (PRWEB) March 31, 2009 -- A plenary panel discussion on the ...
... FREDERICK, Md., March 31 ImQuest Life Sciences ... development of the pyrimidinedione small molecules as antiviral ... Hepatitis and Liver Disease meeting held last week ... identified ten pyrimidinediones as inhibitors of HBV replication, ...
... Codexis, Inc. today announced Lori Giver, Ph.D., has ... Systems Biology for Codexis Bioindustrials. She is responsible ... Dr. Giver reports to David Anton, Ph.D., Vice President, ... researcher in the directed evolution of genes and proteins. ...
Cached Biology Technology:Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 2Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 3Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 4Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 5ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C. 2Codexis Names Lori Giver VP Systems Biology 2
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... report on a new way of preventing potentially harmful plasticizers ... migrating from one of the most widely used groups of ... polyvinyl chloride (PVC) plastics that are safer than those now ... say. Their study is in ACS, Macromolecules , a ...
... 2, 2010 -- A hormone responsible for the body,s stress ... in the pancreas, according to JDRF- funded researchers at the ... are the latest advances to underscore the potential for regeneration ... 1 diabetes. The research, which was published ...
... North Carolina State University have developed a "smart coating" that ... off infection. When patients have hip, knee or dental ... reject the implant. But the smart coating developed at NC ... implant. The coating creates a crystalline layer next to the ...
Cached Biology News:JDRF-funded research advances potential for regeneration as a possible cure for type 1 diabetes 2Smart coating opens door to safer hip, knee and dental implants 2
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Time- and temperature-controlled microwave ... Rehydration and Antigen Retrieval of ... offers ease of use, high ... and high performance. When used ...
... discovery system miniaturizes, integrates and automates ... LabChip technology, the LabChip 3000 performs ... flow fashion. LabChip assays are separations-based, ... what is achievable in homogenous, well-based ...
Biology Products: